These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

41 related articles for article (PubMed ID: 25166216)

  • 1. A pharmacokinetic-viral kinetic model describes the effect of alisporivir as monotherapy or in combination with peg-IFN on hepatitis C virologic response.
    Nguyen TH; Mentré F; Levi M; Yu J; Guedj J
    Clin Pharmacol Ther; 2014 Nov; 96(5):599-608. PubMed ID: 25166216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modeling viral kinetics and treatment outcome during alisporivir interferon-free treatment in hepatitis C virus genotype 2 and 3 patients.
    Guedj J; Yu J; Levi M; Li B; Kern S; Naoumov NV; Perelson AS
    Hepatology; 2014 May; 59(5):1706-14. PubMed ID: 24375768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Profile of alisporivir and its potential in the treatment of hepatitis C.
    Gallay PA; Lin K
    Drug Des Devel Ther; 2013; 7():105-15. PubMed ID: 23440335
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alisporivir, a cyclosporin derivative that selectively inhibits cyclophilin, for the treatment of HCV infection.
    Watashi K
    Curr Opin Investig Drugs; 2010 Feb; 11(2):213-24. PubMed ID: 20112171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
    Butt AA; Kanwal F
    Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cyclophilin inhibitor alisporivir prevents hepatitis C virus-mediated mitochondrial dysfunction.
    Quarato G; D'Aprile A; Gavillet B; Vuagniaux G; Moradpour D; Capitanio N; Piccoli C
    Hepatology; 2012 May; 55(5):1333-43. PubMed ID: 22135208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.
    Kumthip K; Chusri P; Pantip C; Thongsawat S; O'Brien A; Nelson KE; Maneekarn N
    J Med Virol; 2014 Aug; 86(8):1360-5. PubMed ID: 24777626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to interferon-based therapies in HIV-infected patients with chronic hepatitis C due to genotype 4.
    Soriano V; Núñez M; Sánchez-Conde M; Barreiro P; García-Samaniego J; Martín-Carbonero L; Romero M; González-Lahoz J
    Antivir Ther; 2005; 10(1):167-70. PubMed ID: 15751774
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiviral therapy for recurrent hepatitis C after liver transplantation: sustained virologic response is related to genotype 2/3 and response at week 12.
    Raziorrouh B; Jung MC; Schirren CA; Loehe F; Thiel M; Nitschko H; Diepolder H; Ulsenheimer A; Heeg M; Zachoval R; Gruener NH
    Eur J Gastroenterol Hepatol; 2008 Aug; 20(8):778-83. PubMed ID: 18617783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Future perspectives: towards interferon-free regimens for HCV.
    Gane E
    Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of different regions of the hepatitis C virus genome in the therapeutic response to interferon-based treatment.
    Khaliq S; Latief N; Jahan S
    Arch Virol; 2014 Jan; 159(1):1-15. PubMed ID: 23851652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Virologic response and characterisation of HCV genotype 2-6 in patients receiving TMC435 monotherapy (study TMC435-C202).
    Lenz O; Vijgen L; Berke JM; Cummings MD; Fevery B; Peeters M; De Smedt G; Moreno C; Picchio G
    J Hepatol; 2013 Mar; 58(3):445-51. PubMed ID: 23142061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of genotypes and amino acid residues 2209 to 2248 of the NS5A region of hepatitis C virus in relation to the response to interferon-beta therapy.
    Kurosaki M; Enomoto N; Murakami T; Sakuma I; Asahina Y; Yamamoto C; Ikeda T; Tozuka S; Izumi N; Marumo F; Sato C
    Hepatology; 1997 Mar; 25(3):750-3. PubMed ID: 9049230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.
    Xia B; Barve A; Heimbach T; Zhang T; Gu H; Wang L; Einolf H; Alexander N; Hanna I; Ke J; Mangold JB; He H; Sunkara G
    Eur J Pharm Sci; 2014 Oct; 63():103-12. PubMed ID: 25008118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a "capture-fusion" model to study drug sensitivity of patient-derived hepatitis C.
    Cunningham ME; Javaid A; Waters J; Davidson-Wright J; Wong JL; Jones M; Foster GR
    Hepatology; 2015 Apr; 61(4):1192-204. PubMed ID: 25330450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Hepatitis C. An increase in interferon-free therapy].
    Warpakowski A
    MMW Fortschr Med; 2014 Jun; 156 Suppl 1():8. PubMed ID: 25026844
    [No Abstract]   [Full Text] [Related]  

  • 19. Integrated pharmacokinetic/viral dynamic model for daclatasvir/asunaprevir in treatment of patients with genotype 1 chronic hepatitis C.
    Wang HC; Ren YP; Qiu Y; Zheng J; Li GL; Hu CP; Zhou TY; Lu W; Li L
    Acta Pharmacol Sin; 2018 Jan; 39(1):140-153. PubMed ID: 28880015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Individual Bayesian Information Matrix for Predicting Estimation Error and Shrinkage of Individual Parameters Accounting for Data Below the Limit of Quantification.
    Nguyen THT; Nguyen TT; Mentré F
    Pharm Res; 2017 Oct; 34(10):2119-2130. PubMed ID: 28660401
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.